Kevin served 22 years on active duty in the US Navy Medical Service Corps as a Microbiologist specializing in malaria prevention, control, treatment, epidemiology, and immunology research.
He has long focused on Plasmodium vivax malaria, in particular on the problems of G6PD deficiency and cytochrome P-450 2D6 pharmacogenetics regarding the toxicity and efficacy of primaquine therapy against relapse of that species. His laboratory undertakes clinical trials of therapies against relapse of P. vivax, principally in Indonesian soldiers but also in village settings, in addition to laboratory and field studies of G6PD deficiency biochemistry, diagnostics, and epidemiology. Kevin also leads randomized controlled trials of experimental vaccines for the prevention of malaria.
